Rabbit Polyclonal SLC22A6 antibody. Suitable for IHC-P and reacts with Rat samples. Cited in 5 publications. Immunogen corresponding to Synthetic Peptide within Human SLC22A6.
Preservative: 0.025% Sodium azide, 0.025% Thimerosal (merthiolate)
Constituents: 2.5% BSA, 0.45% Sodium chloride, 0.1% Disodium hydrogenorthophosphate
IHC-P | |
---|---|
Rat | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info 0.50000-1.00000 µg/mL | Notes Perform heat-mediated antigen retrieval before commencing with IHC staining protocol. |
Select an associated product type
Secondary active transporter that functions as a Na(+)-independent organic anion (OA)/dicarboxylate antiporter where the uptake of one molecule of OA into the cell is coupled with an efflux of one molecule of intracellular dicarboxylate such as 2-oxoglutarate or glutarate (PubMed:11669456, PubMed:11907186, PubMed:14675047, PubMed:22108572, PubMed:23832370, PubMed:28534121, PubMed:9950961). Mediates the uptake of OA across the basolateral side of proximal tubule epithelial cells, thereby contributing to the renal elimination of endogenous OA from the systemic circulation into the urine (PubMed:9887087). Functions as a biopterin transporters involved in the uptake and the secretion of coenzymes tetrahydrobiopterin (BH4), dihydrobiopterin (BH2) and sepiapterin to urine, thereby determining baseline levels of blood biopterins (PubMed:28534121). Transports prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) and may contribute to their renal excretion (PubMed:11907186). Also mediates the uptake of cyclic nucleotides such as cAMP and cGMP (PubMed:26377792). Involved in the transport of neuroactive tryptophan metabolites kynurenate (KYNA) and xanthurenate (XA) and may contribute to their secretion from the brain (PubMed:22108572, PubMed:23832370). May transport glutamate (PubMed:26377792). Also involved in the disposition of uremic toxins and potentially toxic xenobiotics by the renal organic anion secretory pathway, helping reduce their undesired toxicological effects on the body (PubMed:11669456, PubMed:14675047). Uremic toxins include the indoxyl sulfate (IS), hippurate/N-benzoylglycine (HA), indole acetate (IA), 3-carboxy-4- methyl-5-propyl-2-furanpropionate (CMPF) and urate (PubMed:14675047, PubMed:26377792). Xenobiotics include the mycotoxin ochratoxin (OTA) (PubMed:11669456). May also contribute to the transport of organic compounds in testes across the blood-testis-barrier (PubMed:35307651).
OAT1, PAHT, SLC22A6, Solute carrier family 22 member 6, Organic anion transporter 1, PAH transporter, Renal organic anion transporter 1, hOAT1, hPAHT, hROAT1
Rabbit Polyclonal SLC22A6 antibody. Suitable for IHC-P and reacts with Rat samples. Cited in 5 publications. Immunogen corresponding to Synthetic Peptide within Human SLC22A6.
Preservative: 0.025% Sodium azide, 0.025% Thimerosal (merthiolate)
Constituents: 2.5% BSA, 0.45% Sodium chloride, 0.1% Disodium hydrogenorthophosphate
The SLC22A6 protein also known as organic anion transporter 1 (OAT1) functions mechanically as a transporter that facilitates the movement of organic anions across cell membranes. The protein has a molecular mass of about 56 kDa. Expression of SLC22A6 occurs in various tissues with significant levels in the kidneys where it is found in the basolateral membrane of the renal proximal tubules. This expression profile highlights its key role in renal function particularly in the excretion and detoxification processes.
SLC22A6 plays a role in the renal secretion of endogenous substances and drugs. It is part of the organic anion transporter family and participates in the elimination of molecules such as prostaglandins urate and multiple pharmaceutical agents. By functioning in concert with other transporter proteins SLC22A6 influences the pharmacokinetics of drugs and the clearance of metabolic waste products. Its activity ensures the proper balance of organic anions contributing to homeostasis.
SLC22A6 integrates into the metabolic and excretory pathways in the kidney. It is part of the metabolic detoxification process capturing drugs and metabolites for renal excretion. The transporter works in a network that includes proteins such as SLC22A8 and urate-anion exchanger (URAT1) ensuring efficient substance clearance. In drug metabolism SLC22A6 interaction determines drug disposition with implications for drug efficacy and toxicity.
Researchers have identified SLC22A6 as significantly involved in the pathogenesis of chronic kidney disease (CKD) and hypertension. Variation or malfunction in this transporter can affect the renal excretion of toxic metabolites and drugs contributing to CKD progression. Additionally altered function of SLC22A6 influences blood pressure regulation linking it to hypertension. These associations highlight the importance of SLC22A6 as a therapeutic target in treating renal and cardiovascular disorders.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Immunohistochemical analysis of paraffin embedded Rat kidney tissue labelling SLC22A6 with ab131087 at 0.5 µg/ml.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com